Definitive Contract 75N93022C00060
Award Date 9/21/22
Potential Completion Date 2/8/26
Potential Value $19M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
30
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $15,505,000.31 definitive cost-no-fee contract to Entasis Therapeutics Inc., a subsidiary of Innoviva, Inc., to identify and develop a non-beta-lactam penicillin-binding protein (PBP) inhibitor with broad-spectrum activity against multidrug-resistant Gram-negative ESKAPE pathogens. This work directly responds to a NIAID solicitation for proposals addressing...
- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $3,318,955.00 cost-plus-fixed-fee definitive contract to Locus Biosciences Inc., a clinical-stage biopharmaceutical company, to advance a novel therapeutic to a first-in-human clinical study. This contract does not have a set-aside designation. The awardee, Locus Biosciences Inc., is developing antibacterial therapies using engineered bacteriophages, or viruses that can...
- This $44,503,613.75 cost-plus-fixed-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Venatorx Pharmaceuticals Inc. to advance the development of a novel beta-lactamase inhibitor targeting multidrug-resistant Acinetobacter baumannii. The contract, which has an ultimate completion date of August 31, 2026, supports Venatorx's research and development efforts to create non-beta-lactam inhibitors of penicillin-binding proteins to...
- This is a $575,850.00 fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the In Vitro Antimicrobial Assessments 2011-2018 indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract was awarded to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute located in Seattle, Washington. The contract is for unspecified "OTHER FUNCTIONS" and does not have a set-aside designation. As a prime...
- This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.
- This contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is a Delivery Order under the In Vitro Assessments of Antimicrobial Activity (IVAAA) Indefinite Delivery/Indefinite Quantity (ID/IQ) contract vehicle. The $1,275,123.00 cost-plus-fixed-fee contract is for evaluating therapeutic product...
- The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. government, has awarded a $306,500.00 firm fixed price definitive contract to Fox Chase Chemical Diversity Center Inc., a for-profit pharmaceutical organization. The contract, which does not have a set-aside designation, is for SBIR Topic 134 and has an ultimate completion date of November 14, 2025. Fox Chase Chemical Diversity Center Inc. is an experienced federal contractor, having received...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH NIAID) awarded a $22,595,588.82 cost-plus-fixed-fee definitive contract to Versatope Therapeutics Inc., a for-profit biotechnology company based in Lowell, Massachusetts. This contract, awarded under the HHS-NIH-NIAID-BAA2018 program, supports research to establish and improve biomedical knowledge on infectious diseases such as malaria. The contract has an ultimate completion date of June 28, 2025....
- This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Pharmacology Discovery Services Taiwan, Ltd., a for-profit Taiwanese company. The contract, valued at $1,239,019.00, is a delivery order issued under NIAID's Preclinical Models of Infectious Diseases 2017-2024 indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. Under this delivery order, Pharmacology Discovery...
- This is a firm fixed-price task order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Southern Research Institute, a non-profit organization, under the In Vitro Antimicrobial Assessments 2011-2018 Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle. The task order is for $548,193.00 and is for in vitro antimicrobial assessment services to support NIAID's research and development activities, with a...